Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni

BACKGROUND: The control of schistosomiasis has been centered to date on a single drug, praziquantel, with shortcomings including treatment failure, reinfection, and emergence of drug resistance. Drug repurposing, combination therapy or nanotechnology were explored to improve antischistosomal treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Eissa, Maha M., El-Azzouni, Mervat Z., El-Khordagui, Labiba K., Abdel Bary, Amany, El-Moslemany, Riham M., Abdel Salam, Sara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493353/
https://www.ncbi.nlm.nih.gov/pubmed/32933556
http://dx.doi.org/10.1186/s13071-020-04346-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493353/
https://www.ncbi.nlm.nih.gov/pubmed/32933556
http://dx.doi.org/10.1186/s13071-020-04346-1

Ejemplares similares